. Author manuscript; available in PMC: 2022 Oct 1.

Published in final edited form as: Acta Oncol. 2021 Jul 24;60(10):1308–1316. doi: 10.1080/0284186X.2021.1953137

Table 2:

Outcomes abstracted from included studies.

	Author	Groups	R0 resection%	T downstaging%	pCR%	OS%	DFS/DRTF%
Washington Cohort	Markovina et al. (2017)	Study	NR	75	28	96 (3-year)	80 (3-year)
		Control	NR	41	16	88 (3-year)	70 (3-year)
	Myerson et al. (2014)	Study	NR	71	28	NR	NR
		Control
Polish Cohort	Ciseł et al. (2019)	Study	77	NR	16	49 (8-year)	43 (8-year)
		Control	71	NR	12	49 (8-year)	41 (8-year)
	Bujko et al. (2016)	Study	77	NR	16	73 (3-year)	53 (3-year)
		Control	71	NR	12	65 (3-year)	52 (3-year)
	Bujko et al. (2013)	Study	73	71	21	NR	NR
		Control	71	73	8	NR	NR
Iranian Cohort	Aghili et al. (2020)	Study	100	54.8	32.2	NR	NR
		Control	96.2	53.8	23.1	NR	NR
	Aghili et al. (2018)	Study	NR	NR	30.8	65 (3-year)	55 (3-year)
		Control
Baltimore Cohort	Jia et al. (2019)	Study	69.2	NR	35	NR	NR
Baltimore Cohort		Control
Danish Cohort	Van Dijk et al. (2013)	Study	72	47	26	80 (2-year)	NR
Danish Cohort		Control
RAPIDO trial	Bahadoer et al. (2020)	Study	90	NR	28	89.1 (3-year)	23.7 (3-year DRTF)
RAPIDO trial		Control	90	NR	14	88.8 (3-year)	30.4 (3-year DRTF)
Indian Cohort	Thakur et al. (2020)	Study	92.8	NR	0.071	NR	NR
Indian Cohort		Control	92.3	NR	0	NR	NR

(pCR = pathological complete response; OS = overall survival; DFS = disease free survival, DRTF = disease-related treatment failure, NR = not reported)